Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LY3537021

Peptide · Agonist of Glucose-dependent insulinotropic polypeptide receptor (GIPR) · developed by ELI LILLY &

Phase 2 Most advanced trial

LLY Developer

1 Registered trials

What is LY3537021?

LY3537021 is a long-acting GIPR agonist that is given subcutaneously. It binds and activates the glucose-dependent insulinotropic polypeptide receptor, and it is studied in nausea and vomiting, including nausea and vomiting related to drug side effects in patients with neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Peptide
Targets: Glucose-dependent insulinotropic polypeptide receptor (GIPR)
Mechanism: Agonist of Glucose-dependent insulinotropic polypeptide receptor (GIPR)
Therapy area: Gastroenterology, Oncology
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07169851	Phase 2	Nausea	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Drug-Related Side Effects and Adverse ReactionsNauseaNeoplasmsVomiting

Other drugs acting on GIPR

Tirzepatide FDA approved DehydraTECH-semaglutide Phase 1 Maridebart Cafraglutide Phase 3 VK2735 Investigational

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

NCI Thesaurus

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY3537021

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z